The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Amvuttra ...

The approvals represent the first PD-1 inhibitor plus ADC regimens for this patient population. Treatment involves Keytruda or Keytruda Qlex with Padcev before surgery and continued after cystectomy.

Bayer has reported encouraging topline findings from its global phase 3 OCEANIC-STROKE study, evaluating the investigational ...

The Academy of Medical Sciences and Wellcome have announced a new five-year agreement worth £27.3 million, reinforcing their ...

GSK and the Fleming Initiative have announced six new research programmes to combat antimicrobial resistance (AMR), backed by ...

The European Commission has approved Libtayo (cemiplimab) as the first and only immunotherapy for adult patients with ...

Cellbyte, a Munich-based AI-native platform helping pharmaceutical companies accelerate drug launches, has raised $2.75 ...

“As the first biosimilar to Simponi (golimumab) to gain approval in the European market, we are committed to expanding access ...

Biogen has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has ...

Mursla Bio has announced a new collaboration with a leading global pharmaceutical company to support biomarker-guided drug ...

Poolbeg Pharma has announced that the European Patent Office has granted its European Immunomodulator II patent application ...

Protara Therapeutics has announced encouraging interim results from its ongoing phase 2 STARBORN-1 trial evaluating TARA-002 ...